Assessing the combination of FOLFOX or FOLFIRI with bevacizumab, cetuximab, or both in metastatic colorectal cancer

Alan P. Venook, Charles D. Blanke, Richard M. Goldberg, Denise K. Reinke, Susan Sutherland, John R. Taylor, Pamela McAllister, Richard L. Schilsky

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

This article is the first in a new series that details available clinical trials and offers information on how you and your practice can participate. The CALGB/SWOG 80405 trial is designed to assess the optimal combination of biological agents and chemotherapy for the first-line treatment of patients with advanced or metastatic colorectal cancer.

Original languageEnglish (US)
Pages (from-to)593-598
Number of pages6
JournalCommunity Oncology
Volume3
Issue number9
DOIs
StatePublished - Sep 2006

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Assessing the combination of FOLFOX or FOLFIRI with bevacizumab, cetuximab, or both in metastatic colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Venook, A. P., Blanke, C. D., Goldberg, R. M., Reinke, D. K., Sutherland, S., Taylor, J. R., McAllister, P., & Schilsky, R. L. (2006). Assessing the combination of FOLFOX or FOLFIRI with bevacizumab, cetuximab, or both in metastatic colorectal cancer. Community Oncology, 3(9), 593-598. https://doi.org/10.1016/S1548-5315(11)70756-2